This report brings you information about the use of HBOT to help with symptoms due to Long Haul COVID. Emergency Use Authorization (EUA) can be used to get a drug into use. It was used for COVID vaccines, and is contemplated for immediate use of a drug to deal with Alzheimers. Using HBOT to fight long-haul COVID and the heal brain wounds from TBI/PTSD/Concussion could be done safely, effectively, and immediately. Rules are here.

“Most COVID-19 sufferers fully recover, but after the initial illness approximately 10–20% of patients develop long COVID, also called post-COVID condition or syndrome. Symptoms include shortness of breath, fatigue, cough, chest pain, rapid or irregular heartbeats, body aches, rashes, loss of taste or smell, nausea, vomiting, diarrhea, headache, dizziness, insomnia, brain fog, depression and anxiety. Patients with post-COVID syndrome may also develop cardiac dysfunction and are at increased risk of a range of cardiovascular disorders.”


Hyperbaric Oxygen Therapy forPost-COVID Syndrome

The term “Post-COVID Conditions” is an umbrella term for the wide range of physical and mental health consequences experienced by some patients that are present four or more weeks after SARS-CoV-2 infection, including by patients who had initial mild or asymptomatic acute infection, according to the Centers for Disease Control and Prevention.

Now new research is supporting hyperbaric oxygen therapy (HBOT) has having promising potential to improve the symptoms of long COVID due to its proven anti-inflammatory effects. Scientist say HBOT has been shown to decrease inflammation by suppressing pro-inflammatory and increasing antioxidant gene expression.

Dr Janell Royster, LMHC, LPC interim program manager of the Undersea Oxygen Clinic joined Gayle Guyardo the host of the global health and wellness show Bloom with how the treatment not only helps patients with long term covid symptoms but many other ailments as well.

Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial

Post-COVID-19 condition refers to a range of persisting physical, neurocognitive, and neuropsychological symptoms after SARS-CoV-2 infection. The mechanism can be related to brain tissue pathology caused by virus invasion or indirectly by neuroinflammation and hypercoagulability. This randomized, sham-control, double blind trial evaluated the effect of hyperbaric oxygen therapy (HBOT or HBO2 therapy) on post-COVID-19 patients with ongoing symptoms for at least 3 months after confirmed infection.

These results indicate that HBOT can induce neuroplasticity and improve cognitive, psychiatric, fatigue, sleep and pain symptoms of patients suffering from post-COVID-19 condition. HBOT’s beneficial effect may be attributed to increased brain perfusion and neuroplasticity in regions associated with cognitive and emotional roles.

Hyperbaric oxygen therapy can be beneficial in patients with post-COVID syndrome

A randomized trial using 60 patients with post-COVID syndrome has found that hyperbaric oxygen therapy promotes restoration of the heart’s ability to contract properly. The research is presented at EACVI 2023, a scientific congress of the European Society of Cardiology (ESC). The study suggests that hyperbaric oxygen therapy can be beneficial in patients with long COVID. A sensitive measure of cardiac function which is not routinely performed in all centers was performed. More studies are needed to determine which patients will benefit the most, but it may be that all long COVID patients should have an assessment of global longitudinal strain and be offered hyperbaric oxygen therapy if heart function is reduced.

Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention [here]

Based on initial informal feedback, the 10 patients studied showed positive results in the longer term. Thus, there is a need to assess these effects of HBOT in the context of a randomised placebo-controlled prospective study. However, these initial results suggest that HBOT merits further study as a treatment option for patients presenting with long COVID symptoms (such as fatigue). Given the scale of the emerging long COVID public health emergency globally (estimated 23 million in the US). . . . there is an urgent need for larger-scale randomised placebo-controlled trials to evaluate the potential impact of HBOT in the context of long COVID. In addition, creation of a registry of patients receiving HBOT for long COVID symptoms (such as fatigue) in order to obtain follow-up data over time is also suggested.

Information provided by does not constitute a medical recommendation. It is intended for informational purposes only, and no claims, either real or implied, are being made.

Heal Brains. Stop Suicides. Restore Lives. TreatNOW